Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

EED226, PRC2 Inhibitor

EED226, PRC2 Inhibitor

$139.00
A potent and selective allosteric PRC2 inhibitor that directly binds to the H3K27me3 binding pocket of EED.
Catalog No. Unit Price Qty
M60327-2s 2 mg solid $139.00

Details

Product Information
Molecular Weight: 369.50
Formula: C17H15N5O3S
Purity: ≥98%
CAS#: 2083627-02-3
Solubility: DMSO up to 50 mM
Chemical Name: N-(furan-2-ylmethyl)-8-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month;

Biological Activity:

EED226 is a potent and selective allosteric PRC2 inhibitor that directly binds to the H3K27me3 binding pocket of EED. In the in vitro enzymatic assays, EED226 inhibits PRC2 with an IC50 of 23.4 nM when the H3K27me0 peptide is used as substrate and an IC50 of 53.5 nM when the mononucleosome is used as the substrate. It is noncompetitive with both SAM and peptide substrate. EED226 induces a conformational change upon binding EED, leading to loss of PRC2 activity. EED226 shows similar activity to SAM-competitive inhibitors in blocking H3K27 methylation of PRC2 target genes and inducing regression of human lymphoma xenograft tumors. Interestingly, EED226 also effectively inhibits PRC2 containing a mutant EZH2 protein resistant to SAM-competitive inhibitors, and shows a synergistic effect to inhibit cancer cell growth when combined with EZH2 inhibitors. Such results indicate that targeting the H3K27me3 pocket in EED is a promising approach for treating cancers that are dependent on PRC2 activity.


How to Use:

In vitro: EED226 was used at 10 µM in vitro and cellular assays.
In vivo: EED226 was dosed orally to mice at 4-80 mg/kg twice a day (BID dosing) in subcutaneous Karpas422 xenograft tumor model.

Reference:

  • 1. Qi W, et al. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. (2017) Nat Chem Biol. 13(4):381-388. 
  • 2. Huang Y, et al. Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy. (2017) J Med Chem. 60(6):2215-2226. 
  • 3. Li L, et al. Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED. (2017) PLoS One. 12(1):e0169855. 

EED226_spec.pdf      
EED226_MSDS.pdf      

Products are for research use only. Not for human use. 

Description

Details

Product Information
Molecular Weight: 369.50
Formula: C17H15N5O3S
Purity: ≥98%
CAS#: 2083627-02-3
Solubility: DMSO up to 50 mM
Chemical Name: N-(furan-2-ylmethyl)-8-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month;

Biological Activity:

EED226 is a potent and selective allosteric PRC2 inhibitor that directly binds to the H3K27me3 binding pocket of EED. In the in vitro enzymatic assays, EED226 inhibits PRC2 with an IC50 of 23.4 nM when the H3K27me0 peptide is used as substrate and an IC50 of 53.5 nM when the mononucleosome is used as the substrate. It is noncompetitive with both SAM and peptide substrate. EED226 induces a conformational change upon binding EED, leading to loss of PRC2 activity. EED226 shows similar activity to SAM-competitive inhibitors in blocking H3K27 methylation of PRC2 target genes and inducing regression of human lymphoma xenograft tumors. Interestingly, EED226 also effectively inhibits PRC2 containing a mutant EZH2 protein resistant to SAM-competitive inhibitors, and shows a synergistic effect to inhibit cancer cell growth when combined with EZH2 inhibitors. Such results indicate that targeting the H3K27me3 pocket in EED is a promising approach for treating cancers that are dependent on PRC2 activity.


How to Use:

In vitro: EED226 was used at 10 µM in vitro and cellular assays.
In vivo: EED226 was dosed orally to mice at 4-80 mg/kg twice a day (BID dosing) in subcutaneous Karpas422 xenograft tumor model.

Reference:

  • 1. Qi W, et al. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED. (2017) Nat Chem Biol. 13(4):381-388. 
  • 2. Huang Y, et al. Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy. (2017) J Med Chem. 60(6):2215-2226. 
  • 3. Li L, et al. Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED. (2017) PLoS One. 12(1):e0169855. 

EED226_spec.pdf      
EED226_MSDS.pdf      

Products are for research use only. Not for human use. 

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: